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Viruses cause the majority of respiratory infections. A rapid laboratory 
method to accurately diagnose etiology of respiratory illness can inform 
physicians and guide treatment decisions. The objective of this cross-sectional, 
laboratory based surveillance study is to assess the sensitivity and specificity of 
influenza virus rapid antigen assay Quidel A+B (Quidel, San Diego, CA) and two 
multiplex respiratory pathogen assays [Idaho Technology FilmArray® Respiratory 
Panel (Idaho Technology, Inc., Salt Lake City, UT) and Qiagen ResPlex™ II 
(Qiagen, Germantown, MD)] compared with influenza virus polymerase chain 
reaction (PCR) assays.  
Patients seeking treatment for influenza-like-illness (ILI) in the outpatient 
setting were identified between October 17, 2010 and May 31, 2011. A total of 
1,481 ILI patients were seen. Nasal specimens were collected and tested on all 
assays for 253 of these patients. Sensitivity and specificity of each influenza and 
multiplex respiratory assay was calculated relative to a gold standard PCR assay. 
The self-reported symptom profiles of each organism identified in the respiratory 
pathogen panels were compared.  
The median patient age was 12 years (range: 0-89 years); 176 (70%) had 
one or more viruses detected in the nasal swab specimen. Sensitivity for 
influenza A was 92% (95% CI: 88-99%) for FilmArray® RP, 85% (95% CI: 81-
96%) for ResPlex™ II, and 38% (95% CI: 48-71%) for Rapid, with specificities of 
99.5-100%. Sensitivity for influenza B was 85% (95% CI: 86-99%), 70% (95% CI: 
66-90%) for ResPlex™ II, and 6% (95% CI: 0-23%) for Rapid, with specificities of 
99.5-100%. A similar pattern was seen for noninfluenza viruses, with the 
FilmArray® RP assay being more sensitive and specific than the ResPlex™ II. 
The use of multiplex viral assays is becoming more common in point-of-care 
settings. In this study, the Idaho Technology FilmArray® Respiratory Panel was 
more sensitive and specific than the Qiagen ResPlex™ II assay for influenza A 
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Viral infections cause the majority of respiratory tract illness. Clinical 
symptoms alone do not accurately diagnose the etiologic agent of infection. 
Inappropriate use of antibiotics for viral infections has led to health care 
guidelines with respiratory tract illness algorithms1 to reduce the use of antibiotics 
for treatment of viral illness. While the appropriate use of antivirals can reduce 
the duration and severity of illness2 they are only effective for influenza infections. 
Rapid, accurate laboratory testing can guide diagnosis and treatment decisions in 
the outpatient setting.  
Traditional syndromic surveillance3 has been used to identify illness trends 
in the community to guide health care provider treatment decisions. Syndromic 
surveillance by the University of Utah Primary Care Research Network 
(UUPCRN) is provided electronically to the Utah Department of Health (UDOH). 
The data sent by UUPCRN are a weekly composite of influenza-like-illness (ILI) 
patient visits by the following age groups: <1 year, 1-4 years, 5-17 years, 18-24 
years, 25-64 years, and ≥65 years. UUPCRN’s data are merged with that 
provided by other sentinel providers throughout the state, and the aggregated 
data are published weekly4 to inform healthcare providers about the illness trends 
experienced in the community.  
The evolution of point-of-care testing [rapid and now polymerase chain 




extension of a laboratory-based surveillance study (using additional assays) 
designed to identify the causal agent associated with ILI in the outpatient setting 
during the 2010-11 influenza season. This study was part of an Influenza 
Incidence Pilot (IIP) project by the Centers for Disease Control and Prevention 
(CDC) and the UDOH. The IIP project was funded by the CDC and the Council of 
State and Territorial Epidemiologists (CSTE) for the 2010-11 influenza season at 
12 sites in the United States. In Utah, a contract was awarded to the UDOH, with 
a subcontract to UUPCRN. Patients with ILI who were seen at the UUPCRN 
Urgent Care or the Redwood outpatient clinic were eligible for the study. Study 
specimens were tested at the Unified State Laboratory: Public Health (USLPH), 
the public health laboratory for the UDOH located in Taylorsville, Utah. We 
evaluated the diagnostic characteristics of several potential point-of-care tests. 
For the IIP study, all samples were tested with a point-of-care, rapid 
antigen test for influenza A and B (Quidel A+B, Quidel, San Diego, CA), as well 
as with the CDC Human Influenza Virus Real-time (RT-PCR) Detection and 
Characterization Panel (CDC, Atlanta, GA), an influenza virus PCR assay. All 
samples were further tested using a multiplex respiratory virus panel (Qiagen 
ResPlex™ II, Qiagen, Germantown, MD) to determine the associated etiologic 
agent. This report is a study using the IIP samples to evaluate the sensitivity and 
specificity, relative to PCR, of a new point-of-care test for respiratory viral 
pathogens. Residual specimens from the IIP study were evaluated on the 
FilmArray® Respiratory Panel (RP) (Idaho Technology, Inc., Salt Lake City, UT), 
and the outcomes were compared with those from the Qiagen ResPlex™ II assay. 




and were approved by the United States Food and Drug Administration (FDA) in 










Patient Eligibility and Sample Collection 
 
The UUPCRN has 10 outpatient clinics that provide continuity care, and an 
associated Urgent Care Clinic that operates after hours and on weekends. These 
clinics are located in the Salt Lake City, Utah metropolitan area. There are about 
120,000 patients who are seen within this clinic system for a total of 350,000 
annual visits. Between October 17, 2010 and May 31, 2011, eligible patients 
were those seen for ILI at the Urgent Care or by 2 providers at the Redwood 
Clinic, located in Salt Lake City, Utah. The 2 providers were selected for the IIP 
study because they saw a larger proportion of acutely ill patients within the 
Redwood Clinic. One was a physician board-certified in Internal Medicine and 
Pediatrics, while the other was a Nurse Practitioner in the Family Medicine clinic. 
The maximum number of study patients from whom samples were collected each 
week was 50: the first 30 patients at the Urgent care and the first 10 patients of 
each of the 2 providers. This study was approved by the University of Utah 
(#37465) and the Utah Department of Health Institutional Review Boards (IRB).  
For patients older than 2 years, ILI was defined as presence or history of a 
fever of 100°F or higher accompanied by either cough or sore throat in the 
absence of a known, alternative cause of the symptoms. Because young children 
may not be able to express symptoms such as sore throat, the ILI definition for 




with any associated respiratory symptom, such as cough, sore throat, or rhinitis, 
that was absent another known cause. Patients or their parents were asked at 
visit check-in to complete a brief survey that identified their history of fever and 
respiratory symptoms. The medical assistants used this form to identify patients 
who were eligible for the study, obtain verbal consent, and collect a nasal swab 
specimen. The nasal swab specimens were placed into Remel M5™ (Remel, 
Lenexa, KS) viral transport medium and stored in the clinic laboratory refrigerator 
prior to transport on the same or the next business day. A courier transported the 
specimens on ice packs to USLPH, where the Quidel rapid assay and CDC RT-
PCR assay for influenza were completed within 7 days. Samples were then 
aliquoted and frozen until the end of the study, when the ResPlex™ II and 
FilmArray© RP assays were completed on thawed samples. Samples that had 
discrepant results on the multiplex assays were sent for confirmatory PCR testing 
at CDC (for picornaviruses, coronavirus, and parainfluenza viruses) or Southern 
Nevada Public Health Laboratory (for adenovirus, human metapneumovirus, and 
respiratory syncytial virus). Patient demographics, such as age, sex, and zip code 
were abstracted from the electronic medical record (EMR). 
 
Laboratory Tests 
Refrigerated specimens were tested with the Quidel A+B rapid influenza 
antigen test within 1 week of being collected. When rapid influenza testing was 
completed, the specimens were accessioned into the USLPH Influenza testing 
workflow. Viral ribonucleic acid (RNA) was extracted with the QIAamp Viral RNA 




was tested for Influenza A and B by real-time reverse transcriptase-polymerase 
chain reaction (RT-PCR) on the Applied Biosystems™ 7500 Fast Dx Real Time 
PCR instrument (Applied Biosystems, Foster City, CA), according to the CDC 
Human Influenza Virus Real-time (RT-PCR) Detection and Characterization 
Panel6 package insert. Samples that were positive for influenza A were also 
subtyped as seasonal H1, seasonal H3, or pandemic (PDM) H1 2009.7 When the 
Influenza PCR testing was complete, the specimens were aliquoted (400µL/vial) 
and frozen at -80°C. The weekly PCR data were sent to the UDOH 
epidemiologists to be matched with EMR demographic and self-reported 
symptom data provided by UUPCRN, and sent to the Council of State and 
Territorial Epidemiologists (CSTE). 
The Qiagen ResPlex™ II, version 2.08 Research Use Only (RUO) Panel, 
was used to test the study specimens (see Table 1 for assay-specific pathogens). 
A specimen aliquot was thawed and nucleic acid extracted using the MagnaPure 
Compact Total Nucleic Acid Kit I9 (Roche Applied Sciences, Mannheim, 
Germany) on the Roche MagnaPure Compact instrument. The ResPlex™ II 
primers were used to perform PCR on an Applied Biosystems™ GeneAmp 9700 
PCR system (Applied Biosystems, Foster City, CA). The PCR product was then 
hybridized to beads according to the ResPlex™ II handbook, and analyzed on the 
Luminex® 100 IS system (Luminex, Austin, TX) using the QIAplex MDD software 
(Qiagen, Germantown, MD). The positive cut-off threshold value for each virus 
analyte was calculated for each instrument batch by multiplying the average of 
the 3 negative controls by 6.10 The specimen was considered positive if the mean 




value for the individual virus analyte. The ResPlex™ II data were sent to UDOH to 
be matched to EMR demographic and self-reported symptom data and assay 
results were sent to CSTE in June 2011. 
The specimens were tested with Idaho Technology’s FilmArray® 
Respiratory Pathogen Panel11 (RP); see Table 1 for assay specific pathogens. 
The FilmArray® RP uses a pouch system that contains all needed reagents for 
specimen extraction and PCR on the FilmArray® instrument.12 Nasopharyngeal 
specimens are the specimen source approved by the FDA; the sample type in 













Pathogen FilmArray® RP Resplex™  II
Adenovirus  Yes Yes
Bocavirus   Yes* Yes
Bordetella pertussis Yes No
Chlamydophila pneumoniae Yes No
Coronavirus  Yes Yes
Human Metapneumovirus Yes Yes
Influenza A Yes Yes
Influenza B Yes Yes
Mycoplasma pneumoniae Yes No
Parainfluenza Yes Yes
Picornaviruses Yes Yes
Respiratory Syncytial Virus Yes Yes





The results for the specimens tested on the ResPlex™ II assay and the 
FilmArray® Respiratory Pathogen panel were compared. All discrepant samples 
were sent to another laboratory for testing by PCR to resolve the differences. The 
Southern Nevada Public Health laboratory tested for adenovirus, human 
metapneumovirus, and respiratory syncytial virus; Dr. Dean Erdman’s laboratory 
at the CDC tested for picornaviruses, coronavirus, and parainfluenza viruses.  
The gold standard (defined in Table 2) for influenza and noninfluenza 
viruses was used to compute test characteristics. The gold standard for influenza 
viruses was the ULSPH PCR result. The gold standard for the noninfluenza 
viruses was determined by a combination of results: either agreement between 
the ResPlex™ II and FilmArray® RP, or agreement between the confirmatory 
PCR and one of the multiplex assays.  
 
 











Viruses True Positive True Negative
Influenza Viruses Positive PCR at USLPH Negative PCR at USLPH
Positive by ResPlex™ and 
FilmArray®
Negative by ResPlex™ and 
FilmArray®
or or
Positive by confirmatory PCR and 
one multiplex assay







Statistical Analysis  
 
The picornaviruses were grouped together for comparisons among viruses 
since the FilmArray® RP does not differentiate between rhinovirus and 
enterovirus and the ResPlex™ II rhinovirus and coxsackievirus/enterovirus targets 
cross react,13 making it difficult to distinguish between rhinovirus and enterovirus. 
Specimens positive for more than one virus were not included in the laboratory 
symptom figures since there was no way to determine which virus caused the 
patient symptoms. The laboratory results for adenovirus, human 
metapneumovirus, and parainfluenza virus are not displayed in the symptom 
figures since the number detected for each virus was less than 10.  
Demographics for patients who provided nasal samples were compared 
with those of all patients meeting the ILI case definition in the participating clinics. 
Differences between the groups were evaluated by Chi Square using 
VassarStats: Website for Statistical Computation.14  
The results for the Quidel A+B rapid influenza antigen test, Qiagen 
ResPlex™ II, and Idaho Technology FilmArray® RP were compared to the gold 
standard (PCR) to compute test characteristics, including sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), positive 
likelihood ratio (PLR), and negative likelihood ratio (NLR). The concordances, 
expressed as kappa with 95% confidence intervals (CI), were calculated using 
VassarStats: Website for Statistical Computation.15  
Prior to being seen by a clinical provider, patients self-reported their 




earache, headache, malaise, myalgia, nasal congestion, rhinorrhea, and 
vomiting. We created 2 aggregate groupings: 1 for other respiratory symptoms 
(rhinorrhea, nasal congestion, earache), and 1 for abdominal symptoms 
(abdominal pain, diarrhea, vomiting). The proportion of each self-reported 
symptom or aggregate group was tabulated by virus positivity (based on the 
result from the multiplex testing). For each symptom or symptom grouping, the 
Marascuillo procedure16 was used to test for the equality of symptom proportions 










The total number of patients with ILI seen at the Urgent Care clinic or by 
the 2 primary care physicians participating in the study was 1,481 (patient 
demographics listed in Table 3); the patient ages ranged from 0.11 to 89 years, 
with a median age of 9 years. A total of 265 patient specimens were collected; 
the patient ages ranged from 0.3 to 70 years, with a median age of 12 years. 
Twelve patients were dropped from the analysis because their specimens had 
insufficient volume, had no human cells present, or sample quality was 
unsatisfactory. This left 253 samples from patients for analysis.  
 












5 - 9 18% 17%
10 -19 18% 20%
20 - 49 24% 32%
50 and older 5% 4%
Median* 9 years 12 years
Youngest 0.11 years 0.3 years






The IIP study subjects comprised 17% of the ILI database. The following 
age ranges, as specified in the IIP protocol, were compared to each other: <5 
years, 5-9 years, 10-19 years, 20-49 years, and 50 years and older. The 
proportion of males to females was similar with males comprising 47% of the 
study patients. No statistically significant differences were found between the IIP 




Test characteristics for both influenza A and B were more sensitive and 
specific for FilmArray® RP, followed by ResPlex™II, and then rapid antigen 
(Table 4). For influenza A, the FilmArray® RP had 92% sensitivity, 99.5% 
specificity, and positive and negative predictive values of 98%, with a kappa of 
0.94. For influenza B, the FilmArray® RP had 85% sensitivity, 100% specificity, 
and positive and negative predictive values of 100% and 98%, respectively; with 
a kappa of 0.93. The positive likelihood ratio (PLR = sensitivity/proportion false 
positives) estimates the relative probability of a positive test result in those with 
the disease compared to those without the disease. Negative likelihood ratios 
(NLR = proportion false negative/specificity) were also calculated. Additionally, 
the FilmArray® RP was able to subtype influenza A viruses; the sensitivity for 
influenza A subtypes ranged from 90 - 93%.  
Although a positive result for influenza with a rapid test can be considered 
a true positive, a negative rapid result for influenza in a symptomatic patient 





Table 4. Influenza virus test characteristics for 253 samples tested by FilmArray®  
 





ratios are used to determine the likelihood of having the disease, given a positive 
or negative test result, respectively. Generally, likelihood ratios near 1 indicate  
the test is uninformative in making the diagnosis, while increasingly extreme 
values suggest a higher probability of having (for PLR) or not having (for NLR) 
the disease. These ratios are provided in Table 4, where UTC indicates that the 
ratio could not be calculated because the denominator was zero.  
The noninfluenza viruses detectable by both the FilmArray® RP and the 
ResPlex™ II test characteristics are listed in Table 5. For all viruses, the 
FilmArray® RP had better test characteristics than the ResPlex™ II. Test 
characteristics were fairly similar for human metapneumovirus and parainfluenza, 
but the FilmArray® RP was substantially better for the remaining viruses.  
Viruses Method Sens. Spec. PPV NPV PLR NLR Kappa (95% CI)
(+) (-)
FilmArray® (+) 48 1 92% 99.5% 98% 98% 186 0.08 0.94 (0.88-0.99)
FilmArray® (-) 4 200
ResPlex™ (+) 44 1 85% 99.5% 98% 96% 170 0.15 0.88 (0.81-0.96)
ResPlex™ (-) 8 200
Rapid (+) 20 0 38% 100% 100% 64% UTC 0.62 0.59 (0.48-0.71)
Rapid (-) 32 201
FilmArray® (+) 28 0 85% 100% 100% 98% UTC 0.15 0.93 (0.86-0.99)
FilmArray® (-) 5 220
ResPlex™ (+) 23 1 70% 99.5% 96% 96% 152 0.30 0.78 (0.66-0.90)
ResPlex™ (-) 10 219
Rapid (+) 2 0 6% 100% 100% 88% UTC 0.94 0.10 (0-0.23)
Rapid (-) 31 220
Sens. - sensitivity
Spec. - specificity





PPV - positive predictive value
NPV - negative predictive value
PLR - positive likelihood ratio




Table 5. Noninfluenza viruses comparison of positive and negative results by  
 





Among the 253 samples, 176 (70%) were positive for one or more viral 
pathogens by either FilmArray® RP or ResPlex™ II. No bacterial pathogens were 
detected by the FilmArray® RP assay in any of the study samples. Five percent 
of patients had co-positive infections (see Table 6). The picornaviruses were the 
most common co-infection virus, with nine co-infections detected. The number 
and proportion of samples that were positive for each viral pathogen, excluding 
co-positive infections, are provided in Table 7.    
Viruses Method Sens. Spec. PPV NPV PLR NLR Kappa (95% CI)
(+) (-)
FilmArray® (+) 4 0 80% 100% 100% 100% UTC 0.20 0.89 (0.67-1.0)
FilmArray® (-) 1 248
ResPlex™ (+) 2 1 40% 99.5% 67% 99% 99 0.60 0.49 (0.06-0.92)
ResPlex™ (-) 3 247
FilmArray® (+) 21 0 100% 100% 100% 100% UTC 0.00 1 (1.0-1.0)
FilmArray® (-) 0 232
ResPlex™ (+) 15 1 71% 99.5% 94% 97% 166 0.29 0.80 (0.65-0.94)
ResPlex™ (-) 6 231
FilmArray® (+) 3 0 100% 100% 100% 100% UTC 0.00 1 (1.0-1.0)
FilmArray® (-) 0 250
ResPlex™ (+) 3 1 100% 99.5% 75% 100% 250 0.00 0.86 (0.57-1.0)
ResPlex™ (-) 0 249
FilmArray® (+) 9 0 100% 100% 100% 100% UTC 0.00 1 (1.0-1.0)
FilmArray® (-) 0 244
ResPlex™ (+) 9 3 100% 98.7% 75% 100% 81 0.00 0.85 (0.68-1.0)
ResPlex™ (-) 0 241
FilmArray® (+) 31 1 97% 99.5% 97% 100% 214 0.03 0.96 (0.91-1.0)
FilmArray® (-) 1 220
ResPlex™ (+) 22 9 69% 95.9% 71% 95% 17 0.33 0.66 (0.51-0.80)
ResPlex™ (-) 10 212
FilmArray® (+) 33 2 100% 99.0% 94% 100% 110 0.00 0.97 (0.92-1.0)
FilmArray® (-) 0 218
ResPlex™ (+) 16 0 48% 100% 100% 93% UTC 0.52 0.62 (0.46-0.78)










PLR - positive likelihood ratio
NPV - negative predictive value
PPV - positive predictive value







Table 6. Co-positive pathogens detected in  
 







Table 7. Infection prevalence by virus type for 242 patients  
 











Adenovirus &  Picornaviruses 1
Influenza A H1 2009 &  Coronavirus  1
Influenza A H3 & Influenza B 1
Influenza A H3 & Picornaviruses 4
Influenza B & Adenovirus 1
Influenza B & Picornaviruses 1
RSV & Picornaviruses 4
Pathogens Detected
# Subjects Testing 
Positive (%)
     Adenovirus  4 (2%)
     Coronavirus  19 (8%)
     Human Metapneumovirus 3 (1%)
     Influenza A 48 (19%)
           Influenza A H1 (seasonal) 0 (0%)
           Influenza A H1 2009 9 (4%)
           Influenza A H3 39 (15%)
     Influenza B 30 (12%)
     Parainfluenza 9 (4%)
     Picornaviruses 25 (10%)
     Respiratory Syncytial Virus 27 (11%)






By definition, all study patients had a fever of greater than 100°F, with 
either a cough or sore throat. The symptom questionnaires of influenza positive 
test result patients reported 80% of patients having a cough and 60% of patients 
having a sore throat. Other self-reported symptoms that were associated with 
influenza infection are shown in Figure 1. Excluding chills (which were associated 
with the presence of fever as required by the case definition), nasal congestion, 
rhinorrhea, and myalgia were the most common symptoms for patients with a 
laboratory result of influenza. In general, the proportion of patients reporting any 



















































Symptoms in ILI Patients with 
Influenza Virus Detected






Symptoms in ILI patients who had a positive result for a noninfluenza virus 
are provided in Figures 2 and 3. Among 167 ILI patients who did not have 
influenza, 77 (46%) did not have a detectable respiratory pathogen by any of the 
tests we used. As with influenza infection, cough was a more common symptom 
than sore throat in patients with a noninfluenza virus positive laboratory result 
(Figure 2). The most common symptoms (again, excluding chills) recorded by 
patients infected with a noninfluenza virus were nasal congestion and rhinorrhea 
(Figure 3). Myalgia was also fairly common in patients infected with coronavirus. 
Headache was infrequently reported among patients who did not have influenza 





Figure 2. Frequency of cough and sore throat in 167 ILI patients  












































Study Symptoms in ILI Patients 












Figure 2. Symptoms in 167 ILI patients who had a negative PCR  




The self-reported symptoms of the patients with a single virus or no virus 
detected were evaluated by the Marascuillo procedure to determine if there was a 
relationship between the virus detected and symptoms. The only symptoms 
which varied significantly among the viruses were cough and sore throat (data 
not shown). Patients who were positive for parainfluenza or RSV had a higher 
proportion reporting cough compared to those with no positive virus result. 
Patients who were negative for all viruses on the panel had a higher proportion 





























































































































Molecular detection techniques have been increasing in use and 
availability since the year 2000,18 when real-time PCR assays were routinely 
introduced into clinical microbiology laboratories. Microarray technology targeting 
multiple pathogens at a time is a growing field. This study evaluated 2 separate 
types of microarray technologies: a suspension bead microarray assay (Qiagen 
ResPlex™ II) and a solid-surface array (Idaho Technology FilmArray® 
Respiratory Panel). 
In this study the Idaho Technology FilmArray® Respiratory Panel had 
better test characteristics than the Qiagen ResPlex™ II assay. The FilmArray® 
RP sensitivity ranged from 80%-100%, with concordance expressed as kappa of 
0.86 to 1, depending on the virus, versus a sensitivity of 40%-80% for the Qiagen 
ResPlex™ II, with kappa ranging from 0.49 to 0.86. The FilmArray® RP assay 
included influenza A virus subtyping and three bacterial pathogens Bordetella 
pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumonia not 
available on the ResPlex™ II.  
We found few differences in the proportion of self-reported symptoms by 
type of viral infection, which suggests that the use of syndromic surveillance is 
limited in its ability to discriminate between influenza and other types of viral 




respiratory syncytial virus are severely ill, and the finding in our study that they 
reported cough more often than those with a panel-negative result is not 
unexpected, based on the pathology of their illness. We found that those with a 
panel-negative result reported sore throat more often than those with respiratory 
syncytial virus infection. This finding may be a function of the lower sensitivity of 
PCR tests for picornaviruses,19 which would increase the possibility of 
misclassifying a picornavirus as negative on the multiplex panels. Sore throat20 is 
a common symptom of picornavirus infection. Respiratory syncytial virus is more 
common in young children than in other age groups (59% of positive test results 
were for children under age 5 in our study), which may have meant that parents 
were unaware of the presence of sore throat. This combination may have 
resulted in the finding of a significant difference in reported sore throat between 
those with panel-negative infection and those with respiratory syncytial virus 
infection. 
  
Strengths and Limitations 
 
Our study of patients with influenza-like-illness in a community-based 
setting resulted in a large collection of 253 specimens from patients outside of a 
hospital setting. The specimens were collected by medical assistants at a busy 
clinic with the collection of study specimens in addition to routine duties. The 
potential of selection bias was evaluated by comparing the age and sex of the 
sample to all ILI patients presenting to the clinics participating in the study. No 
statistically significant differences were found, suggesting that selection bias was 




the fact that study participation required a nasal swab and some parents did not 
want this performed on their children.  
In our study, the FilmArray® RP assay was more sensitive than the 
ResPlex™ II assay. Two differences between the assays may account for this 
finding. First, in the FilmArray® RP assay each pathogen target has three 
separate PCR reactions performed and evaluated, compared with one or two 
targets per pathogen in the ResPlex™ II assay. Second, the FilmArray® RP 
software analyzes all of the reactions and provides a clear answer for each 
specimen. The ResPlex™ II assay requires manual data calculations and analysis 
to determine the positive cut-off threshold value for each virus analyte, resulting 
in variability in assigning a positive test result each time the test is run. A third 
possibility had to do with sample quality, because the influenza PCR was run with 
fresh samples, but all other assays were run with samples that had gone through 
one freeze-thaw cycle. A study by Luinstra et al.21 found the viral load of influenza 
A viruses had low levels of viral quantification loss when stored at 4°C for up to 
14 days in viral transport medium; levels of virus started to drop when tested at 
21 days. The specimens in our study were stored and transported at 4°C, and all 
specimens had initial influenza PCR performed within 7 days, and likely had 
minimal degradation, as suggested by the findings of Luinstra et al. Influenza 
viruses were found to have a limited reduction in the viral load when limiting the 
freeze-thaw cycles to less than 4 by Ward et al.22 The specimen aliquots in our 
study had a maximum of 2 freeze thaw cycles prior to multiplex testing and 
confirmatory PCR testing at other labs. While the studies of Luinstra et al. and 




prior to testing, it is possible that the FilmArray® RP assay was more robust than 
the ResPlex™ II assay for frozen samples. Thus, the most appropriate assay 
might depend on whether a sample was fresh or frozen.  
Our study is subject to several limitations. Confirmatory PCR was not 
performed on all the specimens that were positive for noninfluenza viruses. The 
gold standard (Table 2) used to calculate the test characteristics was inferred 
from a combination of assay results. While at least 2 assays were required to be 
positive to assign a positive result to a sample, a single accepted gold standard 
such as PCR would have been preferable but was not available in this study.  
 
Comparison with Other Studies 
 
The samples tested as part of this study resulted in 30% of specimens with 
no pathogen detected. This compares favorably with a large prospective study of 
acute respiratory infections performed at a regional microbiology laboratory in 
Vancouver, British Columbia.23 In the Vancouver study, a total of 1,742 
specimens from inpatient and outpatient populations were evaluated, with 32% of 
specimens negative for all pathogens assayed.  
Adenovirus specimens were low in number and presented a challenge in 
analysis because each multiplex assay detected positive specimens missed by 
the other assay. The FilmArray® RP has been shown to be less sensitive than 
real-time PCR adenovirus assays.24 A study by Pierce et al.25 found the 
FilmArray® RP had difficulty detecting some of the adenovirus serotypes when 
compared with real-time PCR. Neither assay that we used has the accuracy of a 




coronavirus positive specimens in our study (8%) was similar to the 8.3% 
detected in a retrospective study in Queensland children in 2004.26  
The number of RSV infections missed by the ResPlex™ II assay was 
surprising. Relative to the study-defined gold standard (positive by one of the 
multiplex assays plus positive by confirmatory PCR), the ResPlex™ II missed 35 
specimens compared to the FilmArray® RP which missed 10. The new 
technology of Idaho Technology FilmArray® RP has 3 primer sets versus the one 
primer set of the existing usual PCR for detection of RSV. A study by Hayden et 
al. reported a lack of sensitivity to RSV for ResPlex™ II relative to FilmArray® 
RP.27 RSV is a serious illness in the pediatric population under age 2 and the 
elderly. A false negative RSV result would impact the clinical care of a 
hospitalized pediatric patient. A previously published ResPlex™ II sensitivity of 
73%28 for RSV is considerably higher than the sensitivity of 48% found in our 
study. The FilmArray® RP showed a sensitivity of 100% for the detection of RSV 
in our study, similar to another published study.29 
 
Considerations for Clinical Decision-Making 
 
The ResPlex™ II assay requires 55 minutes hands-on time per batch; 1 
batch may contain up to 96 specimens and controls, and the total turn-around 
time is 6 hours per batch. One specimen at a time is run using the FilmArray® RP 
pouch and instrument; the specimen hands-on time is 5 minutes, and the 
instrument runs for about 1 hour per specimen. 
The initial investment in equipment needed to perform PCR laboratory 




FilmArray® RP. The Qiagen ResPlex™ II requires an initial purchase of a nucleic 
acid extraction instrument, thermocycler instrument, heat block, and a Luminex 
100 IS system with the QIAplex MDD software. This total investment is 
approximately $91,000. The ResPlex™ II assay requires purchasing laboratory 
consumables in addition to the nucleic acid extraction kits and ResPlex™ II 
reagent kits. The individual specimen cost for the ResPlex™ II ranges from $74 - 
$364 depending on the number of specimens per batch. The Idaho Technology 
FilmArray® RP requires the purchase of a FilmArray® instrument for 
approximately $45,000. The FilmArray® RP kit contains the laboratory 
consumables required for testing and the individual specimen cost is $132 per 
pouch (assay). The ResPlex™ II assay requires a high level of technical expertise 
to perform the assay and a longer turn-around time of 6 hours after nucleic acid 
extraction. The FilmArray® RP requires a low level of technical expertise and 
about 1 hour per specimen. The FilmArray® RP higher cost per pouch could be 
compensated for by the lower initial investment in instrumentation, lower amount 
of hand-on time, and lower level of technical expertise needed to run the assay. 
Rapid antigen influenza assays are considerably less sensitive than PCR 
assays for detecting influenza virus infections. Rapid influenza assays are used 
as point-of-care tests since they are inexpensive and have a quick turn-around-
time to result. The low negative predictive value and sensitivity are a problem, 
with negative results potentially impacting patient treatment decisions due to the 
inability to distinguish between true and false negatives. The PCR-based assays 
FilmArray® RP and ResPlex™ II were more sensitive than the rapid antigen 




designed and provided by CDC, detected more positive Influenza A and Influenza 
B specimens than either multiplex PCR assay. A single PCR assay is typically 
more sensitive than multiplex assays but lacks the ability to detect additional 
pathogens at the same time.30 The multiplex assays detected an additional 102 
viruses (40%) in the study patients. The FilmArray® RP performed better than the 
ResPlex™ II; both are multiplex assays designed to detect multiple pathogens in a 
single specimen. Additionally, the FilmArray® RP assay also provided Influenza 
A subtyping results, which has implications for anti-viral treatment decisions31 by 
clinicians. The FilmArray® RP has a 1-hour turn-around-time, making it more 
amenable to point-of-care testing, relative to the ResPlex™ assay which requires 




ILI symptoms alone are not a good predictor of respiratory tract illness 
pathogen infection, even during a local outbreak of influenza virus.32 Rapid and 
accurate laboratory testing is needed to provide clinicians with laboratory 
information for diagnosis and treatment decisions. The FilmArray® Respiratory 
panel provides sensitive, specific, and rapid test results, with better test 
characteristics than either the Quidel A+B Rapid Antigen test or the Qiagen 
ResPlex™ II assay. The FilmArray® RP was approved by the United States FDA 
on May 15, 201233 for 21 viral and bacterial targets. The high initial cost of 
instrumentation for PCR-based laboratory assays currently limits the use of the 




needed to calculate the true cost of PCR tests in relation to patient treatment 
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